Meeting
2018 Genitourinary Cancers Symposium
Activity of third line (3L) therapy in patients with metastatic non-clear-cell renal cell carcinoma (mnccRCC).
Authors
Annalisa Guida
Institut Gustave Roussy, Villejuif, France
Annalisa Guida , Gwénaël Le Teuff , Emeline Colomba , Carolina Alveosta Silva , Flore Salviat , Giulia Baciarello , Lisa Derosa , Yohann Loriot , Karim Fizazi , Mario Di Palma , Christophe Massard , Bernard Escudier , Laurence Albiges
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 650)
DOI
10.1200/JCO.2018.36.6_suppl.650
Abstract #
650
Poster Bd #
J1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
The survival outcomes of metastatic non-clear cell renal cell carcinoma in the immunotherapy era: Princess Margaret Cancer Centre (PMCC) experience.
First Author: Esmail Mutahar Al-Ezzi
Poster
2023 ASCO Annual Meeting
Proposition of a drug score to predict the clinical usefulness of therapeutic dose monitoring of oral molecularly targeted therapies.
First Author: Arthur Geraud
Poster
2021 Genitourinary Cancers Symposium
Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC).
First Author: Jeffrey Graham
Poster
2021 Genitourinary Cancers Symposium
Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).
First Author: Giuseppe Procopio